...
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis
【24h】

Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis

机译:症状颅内狭窄的医疗与血管内治疗。 贝叶斯网络元分析

获取原文
获取原文并翻译 | 示例
           

摘要

Intracranial stenosis is a well-established stroke risk factor with an increase of stroke recurrence or TIA up to 12.6% at 1 year. Treatments are different: medical and endovascular. We performed a multiple treatment comparison analysis to detect the best treatment in reducing the risk of stroke recurrence. We searched in Medline, Embase, Cochrane Central Register of Controlled Trials databases between 1979 and October 2017. Inclusion criteria were prospective randomized trials that evaluated patients with TIA or stroke due to intracranial stenosis and treated with different medical therapies and/or endovascular procedures. Primary endpoint was the recurrence of TIA or stroke in the territory of intracranial stenosis, while secondary endpoint was represented by any stroke or vascular death. Multiple treatment comparison meta-analysis based on a Bayesian fixed and random effects Poisson model was performed. Seven trials were included with a total of 1337 patients. At multiple treatment comparison, no significant differences between treatments were observed for both primary (median fixed effect standard OR: 0.40; 95%CI: 0.02-1.07) and secondary endpoints (median random effect standard OR: 1.17; 5%CI: 0.32-1.92). Treatment with aspirin alone ranked with high values both for primary and secondary endpoints (surface under the cumulative ranking curve of 70% and 82%, respectively). In patients with symptomatic intracranial stenosis, no differences between treatments were observed. However, aspirin alone was more effective than stenting in the reduction of TIA or stroke recurrences, with a better safety profile than oral anticoagulants. (C) 2019 Elsevier Ltd. All rights reserved.
机译:颅内狭窄是一种成熟的卒中危险因素,其卒中复发或TIA在1年内高达12.6%。治疗不同:医学和血管内。我们进行了多种治疗比较分析以检测降低卒中复发风险的最佳处理。我们在1979年至2017年至10月期间搜索了Medline,Embase,Cochrane中央登记册。纳入标准是前瞻性随机试验,该试验评估了由于颅内狭窄和用不同的医疗治疗和/或血管内程序治疗患有TIA或中风的患者。初级终点是颅内狭窄境内TIA或中风的复发,而次要终点由任何中风或血管死亡表示。基于贝叶斯固定和随机效应泊松模型的多种治疗比较荟萃分析。共有七项试验,共有1337名患者。在多种治疗比较下,对初级(中位固定效应标准或:0.40; 95%CI:0.02-1.07)和次要终点(中位随机效应标准或:1.17; 5%CI:0.32 - 1.92)。单独用阿司匹林对初​​级和次要终点(表面下的累积排名曲线分别为70%和82%)的高值进行治疗。在患有症状颅内狭窄的患者中,观察到治疗之间的差异。然而,只有阿司匹林比在减少TIA或中风复发中的延伸更有效,具有比口腔抗凝血剂更好的安全性。 (c)2019年elestvier有限公司保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号